News

CV6 Therapeutics Featured in the NI Edition of the 12 Clusters of Tech

5th January 2021

Belfast, UK. 5th January, 2021. CV6 Therapeutics, a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases,  have been featured in the November 2020 special report on the ‘12 Clusters of Tech’, a national campaign to champion leading clusters of UK technology led by the UK Tech Cluster […]

Read More

CV6 Therapeutics Inc Recognised as a Platinum Level Innovator

4th January 2021

Belfast, UK. 4th January, 2021. CV6 Therapeutics, a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that they have been recognised as a Platinum Level Innovator by Innovate Northern Ireland on behalf of the Department of the Economy for Northern Ireland. The award was based […]

Read More

CV6 CEO Invited to Participate in Leading Biotech Europe CEO Event

15th March 2019

Belfast, UK. 15th March, 2019. CV6 Therapeutics Inc., a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that CEO and Founder Dr Robert Ladner has been invited to participate in the Europe CEO networking forum in Vienna, Austria on the 24th of March, 2019. Europe CEO is […]

Read More

CV6 CEO to Present at Biotech Showcase™ 2019 in San Francisco

7th January 2019

Belfast, UK. 7th January, 2019. CV6 Therapeutics Inc., a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that it will be featured as a presenting company at Biotech Showcase™ 2019, to be held on the 7th-9th January at the Hilton San Francisco Union Square. […]

Read More

CV6 to Present Details of CV6-168 at Molecular Targets and Cancer Therapeutics Symposium  

25th September 2018

Belfast, UK. 25 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, today announced they would be presenting details on CV6-168, a novel anticancer therapeutic at the 30th EORTC/AACR/NCI Molecular Targets and Cancer Therapeutics Symposium in Dublin, Ireland on 16th of November 2018. The abstract […]

Read More

CV6 CEO Presents at Prestigious Heidelberger Symposium on Cancer Research

18th September 2018

Belfast, U.K. – 18 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, announced today that Dr. Robert Ladner, CEO and Founder, was invited to present the Company’s ground-breaking research that led to the development of the novel dUTPase inhibitor and clinical drug […]

Read More

CV6 CEO Speaks at Patrick Johnston QUB Memorial Symposium

18th May 2018

Belfast, UK. 17 May, 2018. Robert Ladner, CEO and Founder of CV6 Therapeutics Ltd (CV6), paid tribute today to Professor Patrick G. Johnston at a memorial symposium hosted by Queen’s University Belfast to honour and celebrate the life and accomplishments of “A Leader and Innovator in Cancer Research and Treatment”. Patrick, or ‘Paddy’ to those who […]

Read More

CV6 Therapeutics Strengthens Scientific Advisory Board with Recent Appointments

17th May 2018

Belfast, U.K. – May 17, 2018. CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of two new members to their Scientific Advisory Board. Paul Workman, PhD, Chief Executive and President of The Institute of Cancer Research (ICR), London, UK. […]

Read More

CV6 Therapeutics Appoints Richard Milliken as Board Chairman

19th March 2018

Belfast, U.K. – March 19, 2018.  CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of Richard Milliken, CA as Chairman of the Board of Directors. “We are pleased to welcome Richard as our Board Chairman, his extensive experience […]

Read More

CV6 Therapeutics Appoints Chris Rivera to Board

17th March 2018

Belfast, U.K. – April 19, 2018. CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of Chris Riviera to the Board of Directors. “We are pleased to welcome Chris to our Board. Chris brings extensive experience in the pharmaceutical […]

Read More